RxDoctor Payments Data

Luis Arroyo, MD

Cardiovascular Disease · Tampa, FLNPI 1811965650

Payments from drug & device makers

$1,405in general payments, 2019–2025

Across 36 payments — averaging $39.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$289
  • Boston Scientific$253
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$149
  • Itamar Medical Inc$146
  • Alnylam Pharmaceuticals Inc.$125
  • Cvrx, Inc.$122
  • plus $320 from 7 others

What the payments were for

  • Food & beverage$1,405100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,405 in reported general payments places this provider in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$75,978
Medicare patients
299
Services billed
993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis17$377,914
EntrestoSacubitril/Valsartan183$264,247
FarxigaDapagliflozin Propanediol124$170,187
JardianceEmpagliflozin74$101,085
EliquisApixaban84$92,735
OzempicSemaglutide34$35,268
Repatha SureclickEvolocumab29$32,635
XareltoRivaroxaban11$17,817
Tacrolimus151$15,341
Sirolimus29$12,120
CorlanorIvabradine Hcl21$11,805
Mycophenolate Mofetil33$7,450
Mycophenolic AcidMycophenolate Sodium51$6,133
Praluent PenAlirocumab11$5,041
Amiodarone Hcl47$2,774

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$38$470,649101 claims
NovartisEntresto$25$264,247183 claims
Johnson & JohnsonXarelto$22$17,81711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →